Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

YARS2 antibody (C-Term)

This Rabbit Polyclonal antibody specifically detects YARS2 in WB and IHC (p). It exhibits reactivity toward Human and has been mentioned in 3+ publications.
Catalog No. ABIN1882153

Quick Overview for YARS2 antibody (C-Term) (ABIN1882153)

Target

See all YARS2 Antibodies
YARS2 (Tyrosyl-tRNA Synthetase 2, Mitochondrial (YARS2))

Reactivity

  • 24
  • 13
  • 5
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
Human

Host

  • 25
  • 1
Rabbit

Clonality

  • 26
Polyclonal

Conjugate

  • 19
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This YARS2 antibody is un-conjugated

Application

  • 18
  • 9
  • 6
  • 4
  • 4
  • 4
  • 3
Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone

RB14936
  • Binding Specificity

    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 399-427, C-Term

    Predicted Reactivity

    M, Rat

    Purification

    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

    Immunogen

    This YARS2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 399-427 amino acids from the C-terminal region of human YARS2.

    Isotype

    Ig Fraction
  • Application Notes

    WB: 1:1000. IHC-P: 1:10~50

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-20 °C

    Expiry Date

    6 months
  • Riley, Menezes, Rudinger-Thirion, Duff, de Lonlay, Rotig, Tchan, Davis, Cooper, Christodoulou: "Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia." in: Orphanet journal of rare diseases, Vol. 8, pp. 193, (2014) (PubMed).

    Riley, Cooper, Hickey, Rudinger-Thirion, McKenzie, Compton, Lim, Thorburn, Ryan, Giegé, Bahlo, Christodoulou: "Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome." in: American journal of human genetics, Vol. 87, Issue 1, pp. 52-9, (2010) (PubMed).

    Bonnefond, Frugier, Touzé, Lorber, Florentz, Giegé, Sauter, Rudinger-Thirion: "Crystal structure of human mitochondrial tyrosyl-tRNA synthetase reveals common and idiosyncratic features." in: Structure (London, England : 1993), Vol. 15, Issue 11, pp. 1505-16, (2007) (PubMed).

  • Target

    YARS2 (Tyrosyl-tRNA Synthetase 2, Mitochondrial (YARS2))

    Alternative Name

    YARS2

    Background

    YARS2 catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).

    Molecular Weight

    53199

    NCBI Accession

    NP_001035526

    UniProt

    Q9Y2Z4
You are here:
Chat with us!